REPORT TO: TRUST BOARD

DATE: 20 DECEMBER 2013

REPORT FROM: ANDREW SEDDON - DIRECTOR OF FINANCE & BUSINESS SERVICES

SUBJECT: 2013/14 FINANCIAL PERFORMANCE - APRIL TO NOVEMBER 2013

(MONTH 8)

1. INTRODUCTION

1.1. This paper summarises the Month 8 financial position. As well as the following commentary, this report contains a number of key financial statements included within Appendix 1:

- Income and Expenditure
- Balance Sheet
- Cash Flow
- Capital Programme
- November Actuals against November Forecast

2. FINANCIAL POSITION AS AT END OF NOVEMBER 2013

2.1. The Trust is reporting;

- A deficit at the end of November 2013 of £20.3m, which is £23.0m adverse to the planned surplus of £2.7m.
- In month position is a £3.0m deficit, £3.5m adverse to Plan.
- The forecast for November was a deficit of £2.5m, therefore the November actuals reflect a £0.5m adverse position to forecast. The key drivers behind this were an over-achievement on income, offset by adverse variances on expenditure.

Table 1: Income & Expenditure Position

	No	vember 20	13	April -November 2013			
			Var			Var	
			(Adv) /			(Adv) /	
	Plan	Actual	Fav	Plan	Actual	Fav	
	£m	£m	£m	£m	£m	£m	
Income							
Patient income	53.8	58.4	4.6	425.6	434.4	8.8	
Contigency Release	-	-	-	5.0	5.0	-	
Teaching, R&D	5.7	5.6	(0.1)	51.2	50.5	(0.6)	
Other operating Income	1.6	1.6	0.0	25.7	25.7	0.1	
Total Income	61.1	65.7	4.5	507.4	515.7	8.3	
Operating expenditure							
Pay	37.2	39.6	(2.4)	298.8	312.2	(13.4)	
Non-pay	23.9	25.4	(1.5)	184.1	194.8	(10.7)	
Reserves	(4.1)	-	(4.1)	(7.6)	-	(7.6)	
Total Operating Expenditure	57.0	65.0	(8.0)	475.3	507.1	(31.7)	
			(2.5)			(2.2.1)	
EBITDA	4.2	0.7	(3.5)		8.6	(23.4)	
Net interest	0.0	-	(0.0)	0.0	(0.0)	0.0	
Depreciation	(2.7)	(2.7)	(0.0)	(21.7)	(21.5)	0.2	
PDC dividend payable	(1.0)	(1.0)	(0.0)	(7.7)	(7.4)	0.3	
Net deficit	0.5	(3.0)	(3.5)	2.7	(20.3)	(23.0)	
EBITDA %	·	1.1%	·		1.7%	·	

2.2. The **key points** to highlight in the YTD position are:

- Patient care income £8.8m (2.0%) favourable against Plan
- Pay costs, £13.4m (4.5%) adverse to Plan
- Non pay costs, £10.7m (5.8%) adverse to Plan
- Adverse variances to Plan in all CMGs, with the exception of Women's & Children's

The **Month 8 YTD position** are analysed below.

3. INCOME

- 3.1. Within patient income, NHS income is £5.5m (1.5%) above Plan year to date. The key areas are shown in the following table:
 - Elective IP activity is 2.3% down on Plan
 - Emergency IP activity 3.5% up on Plan, but income is £378k (0.8%) adverse
 - Over-performance in outpatients, £2.7m (4.8%)
 - Other income:
 - Critical care, £2.2m, 7% over performing
 - Direct access Imaging and Pathology, £0.2m, 2%
 - End Stage Renal Failure, £1.0m, 5%
 - Excluded drugs and devices, £2.6m, 6%
 - Contractual penalties, £1.3m, offsetting the above favourable variances

Table 3: Patient Care Activity

				Variance				
	Plan to		Variance	YTD	Plan to		Variance	Variance
	Date	Total YTD	YTD	(Activity	Date	Total YTD	YTD	YTD
Case mix	(Activity)	(Activity)	(Activity)	%)	(0003)	(000 2)	(0003)	(Activity %)
Day Case	54,407	56,824	2,417	4.44	33,306	34,489	1,182	3.55
Elective Inpatient	15,307	14,955	(352)	(2.30)	47,270	47,648	378	0.80
Emergency / Non-elective Inpatient	62,782	64,977	2,195	3.50	117,781	118,111	329	0.28
Marginal Rate Emergency Threshold (MRET)	0	0	0	0.00	(2,274)	(3,449)	(1,175)	0.00
Outpatient	494,252	512,313	18,061	3.65	55,901	58,608	2,707	4.84
Emergency Department	105,475	103,459	(2,016)	(1.91)	11,322	11,332	11	0.10
Winter Monies	0	0	0	0.00	0	3,091	3,091	•
Other	5,157,133	5,360,056	202,922	3.93	157,415	160,731	3,316	2.11
Grand Total	5,889,355	6,112,583	223,228	3.79	420,721	430,560	9,839	2.34

3.2. Table 4 below highlights the impact of price and volume changes in activity across the major "points of delivery". Overall, excluding the winter monies, this shows that the £6.7m Trust level over-performance is as a consequence of a volume (activity) related £9.6m favourable impact, lessened by a £2.9m adverse shift in average tariff prices.

Table 4: Price and Volume Impact on Patient Care Activity

Average tariff	Price Variance YTD %	Volume Variance YTD %	Price / Mix Variance (£000)	Volume Variance (£000)	Variance YTD (£000)
Day Case	(0.9)	4.4	(297)	1,480	1,182
Elective Inpatient	3.2	(2.3)	1,465	(1,087)	378
Emergency / Non-elective Inpatient	(3.1)	3.5	(3,790)	4,119	329
Marginal Rate Emergency Threshold (MRET)			(1,175)	0	(1,175)
Outpatient	1.1	3.7	664	2,043	2,707
Emergency Department	2.0	(1.9)	227	(216)	11
Winter Monies			0	3,091	3,091
Other			0	3,316	3,316
Grand Total	(1.4)	3.8	(2,906)	12,745	9,839

- 3.3. Whilst the volume increase in emergency activity reflects the patient activity, the price variance of £2.9m (3.3%) needs greater analysis. The CMGs are investigating the reasons at a specialty and sub-specialty level and we will orally update the Finance & Performance Committee. At this time, the income for month 8 is still based on the early cut information in both months 6 and 7 we saw a £1m improvement at the fully coded stage.
- 3.4. Within the year to date income position, we have made provision for the following penalties. Year to date, this amounts to just over £4.4m, £1.3m if we exclude readmissions.

Table 5: Penalties, deductions & performance fines

	Reported
	in M8
	Position
	£'000s
EM Readmissions	3,080
RTT	797
Diagnostic Imaging	17
Never Events	6
Pressure Ulcers	57
Cancelled Ops	59
ED Wait Times (automatic)	224
ED 12 Hour Trolley Breaches	5
Cancer 62 Day Target (Automatic)	50
Contract Penalties Provision	110
Total	4,405

3.5. The key RTT penalties relate to General Surgery, ENT, Ophthalmology and Orthopaedics. As can be seen from the table, at the moment, we are assuming full reinvestment of any performance fines or other penalties around Ambulance Turnaround times, and the ED and RTT rapid action plans, and this position is consistent with our main commissioners.

4. EXPENDITURE

- 4.1. Operating expenditure is £31.7m above Plan as at the end of November (6.7%).
- 4.2. CMGs and Corporate Directorates have identified a total of £22.2m CIP savings delivered year to date, £0.8m adverse to the £23.0m CIP Plan. The 2013/14 CIP paper considered by F&P committee provides further details on the CIP performance to date, year end forecasts, remedial action plans and RAG ratings for the remaining schemes.

4.3. **PAY** – as at Month 8, pay costs are £13.4m over budget, £16.7m more than the same period in 2012/13 (5.7%). When viewed by staff group, the most significant increases year on year are seen across agency and medical locums, nursing spend and consultants' costs (see below).

Table 6

Staff Type	2013/14	2012/13	Chan	ge
Stall Type	£'000s	£'000s	£'000s	%
A&C / Managers	39,094	39,917	823	2.1
Agency / Medical Locums	15,018	11,268	(3,749)	(33.3)
Allied Health Prof's	12,516	12,509	(7)	(0.1)
Medical - Non Consultant	41,915	40,519	(1,397)	(3.4)
Consultant	59,282	53,796	(5,486)	(10.2)
Nursing & Midwifery	115,797	109,864	(5,933)	(5.4)
Other	28,586	27,593	(992)	(3.6)
TOTAL	312,207	295,466	(16,741)	(5.7)

4.4. Analysis of the year to date £13.4m variance to Plan highlights the following key factors, and split by CMG (the table below excludes Corporate Directorates and Research & Development):

				M1-8	Year on	
				actuals	year	Year on
	YTD Budget	YTD Actuals	Variance	2012/13	change	year
	£000s	£000s	£000s	£000s	£000s	change %
C.H.U.G.S	30,331	30,824	(494)	29,363	(1,461)	(5.0%)
Clinical Support & Imaging	44,867	46,257	(1,390)	44,892	(1,365)	(3.0%)
Divisional Management Codes	2,632	2,533	99	2,512	(21)	(0.8%)
Emergency & Specialist Med	42,307	48,872	(6,565)	41,322	(7,550)	(18.3%)
I.T.A.P.S	33,359	36,320	(2,960)	33,867	(2,453)	(7.2%)
Musculo & Specialist Surgery	29,049	29,992	(943)	29,521	(471)	(1.6%)
Renal, Respiratory & Cardiac	37,409	38,746	(1,336)	37,771	(974)	(2.6%)
Womens & Childrens	49,600	49,564	36	47,083	(2,480)	(5.3%)
Total	269,554	283,106	(13,553)	266,331	(16,776)	(6.3%)

- Estimated pay over-spend due to patient care activity over-performance £4.8m, assuming that pay stepped/marginal cost is c50% of patient care income volume variance and staffed at non-premium rates
- Declared under-delivery on pay CIP schemes £2.5m
- Continued use of extra capacity wards (Fielding Johnson, Ward 1 LRI, Ward 2 LGH, Ward 19 LRI and Odames LRI) to meet the emergency activity levels. Premium spend has covered a significant amount of the staff costs in these areas. Nursing incentives are also being paid to bank and agency to increase the "fill rates", although these are now restricted to the Emergency Care CMG
- **Increased doctors and nurses** in Medicine and ED to ensure the flow of patients from ED to support the 4 hour target. That CMG's pay spend is now £6.6m adverse to plan and almost £7.6m (18%) above that for the same period last year.
- A continued reliance on premium payments as per Chart 1 below. Premium rate costs have increased in this financial year, climbing to almost £4m in May and June, falling to £3.5m in July, and remaining around this level during August and September. Table 7 illustrates the relative percentages of total pay spend of each type. It can be seen that there has been a significant rise in the total percentage to almost 10% in Quarter 1 of

this financial year (falling to 9% in Month 6, but increasing again in October and November).

Chart 1: Non-Contracted/Premium Pay Spend





Table 7: Non-Contracted Pay Costs as %age of Total Pay Bill

Туре	12/13 Q1	12/13 Q2	12/13 Q3	12/13 Q4	13/14 Q1	13/14 M6	13/14 M7	13/14 M8
Bank	1.5%	1.7%	1.8%	1.6%	1.7%	1.6%	1.6%	1.7%
Locums	1.0%	1.3%	1.2%	1.5%	1.5%	1.6%	1.6%	1.6%
Overtime	0.8%	0.8%	1.0%	1.1%	1.0%	1.1%	1.2%	1.1%
WLI	0.8%	0.8%	0.8%	0.8%	1.0%	1.2%	1.1%	0.8%
Agency	2.5%	3.7%	3.8%	3.6%	4.5%	3.5%	4.4%	4.4%
Total	6.6%	8.2%	8.7%	8.5%	9.8%	9.0%	9.9%	9.6%

4.5. Nursing and related agency costs make up the largest part of the adverse pay variance. Some of the overspend, as described above, is volume related (extra capacity opened) and the impact of agency rates is clear. Increase in nurse:bed ratios have also pushed up costs.

Chart 2: Monthly Pay Costs



4.6. The continued reliance on premium staff comes at the same time as our contracted staff numbers in medical and nursing professions have increased by 6.0%, equivalent to an increase of 378 WTE since March 2012 (Table 8). We are continuing to analyse the increase in Consultant numbers of 53wte, or 10%.

Table 8: Contracted WTE

Staff Type	Movement I March		Contracted Staff		
Starr Type			Nov 13	March 12	
	WTE	(%)	WTE	WTE	
ADMIN & CLERICAL	(25)	(1.4)	1,762	1,787	
ALLIED HEALTH PROFESSIONALS	7	1.5	465	458	
CAREER GRADES	10	14.7	80	70	
CONSULTANT	53	10.0	586	533	
HEALTHCARE ASSISTANTS	26	11.8	243	217	
HEALTHCARE SCIENTISTS	(15)	(2.0)	726	741	
MAINTENANCE & WORKS	1	10.6	7	6	
NURSING QUALIFIED	25	0.8	3,374	3,348	
NURSING UNQUALIFIED	227	19.0	1,422	1,195	
OTHER MEDICAL & DENTAL STAFF	36	4.0	935	899	
OTHER SCIEN, THERAP & TECH	63	23.0	337	274	
SENIOR MANAGERS	(36)	(21.0)	135	171	
TOTAL	373	3.8	10,072	9,699	
MEDICAL & NURSING	378	6.0	6,640	6,262	
OTHER STAFF GROUPS	(5)	(0.1)	3,432	3,437	
TOTAL	373	3.8	10,072	9,699	

- 4.7. **NON PAY** operating non pay spend, excluding reserves, is now showing a YTD adverse position to Plan of £10.7m (6%).
- 4.8. This is as a result of three main factors:
 - Activity related marginal costs e.g. keeping Ward 19 open £2.4m (assuming that non pay marginal cost is c25% of patient care income variance)
 - Patient care income backed costs such as NICE/HCT costs £2.6m e.g. haemophilia patients, high cost devices in Renal. Respiratory and Cardiac CMG and Women's & Children's CMG.
 - Other cost pressures/over-stated non-pay CIP delivery £5.7m. This includes:
 - £1.0m Imaging and laboratory non pay consumables
 - £1.4m Use of independent sector and contracted clinical services
 - £0.4m Blood products
 - £0.6m Printing, stationery and postage
 - £0.3m Security
 - £0.6m Maintenance and MES costs
 - £0.7m Consultancy
 - £0.4m Furniture, office equipment and IT
- 4.9. As well as the operating non pay deficit of £10.7m, there is an in-month adverse variance of £4.1m (cumulative £7.6m) against reserves. This heading primarily includes costs relating to the underlying deficit identified through the annual planning cycle. Further in-year pressures and agreed changes, including the investment in the nursing budgets, the re-basing of the initial £40.4m CIP target for "over heating" issues, and additional cost pressures supported post AOP submission e.g. CQUIN posts have added to the adverse variance in this account.

5. CMG AND CORPORATE DIRECTORATE


5.1. The table below shows the in month variance from the Month 8 forecast by CMG and Corporate Directorate. The detailed breakdown by pay, non-pay and income is shown within the appendices.

	Variance compared to forecast - November
	Total £'000s
C.H.U.G.S	76
Clinical Support & Imaging	(234)
Divisional Management Codes	(4)
Emergency & Specialist Med	138
I.T.A.P.S	(363)
Musculo & Specialist Surgery	(124)
Renal, Respiratory & Cardiac	(21)
Womens & Childrens	476
Total CMGs	(57)
Communications & Ext Relations	(9)
Corporate & Legal	26
Corporate Medical	(24)
Facilities	70
Finance & Procurement	22
Human Resources	22
Im&T	(47)
Nursing	33
Operations	81
Strategic Devt	(15)
Total Corporate Directorates	159
Total Central	(607)
Research & Development	11
Grand Total	(495)

5.2. The explanation of the material movements by CMG have been expanded upon in the report to F&P committee. The central position includes an offset against the improvement in final coded patient care income position. The final coded position is of almost £1m better than the early cut and is reflected in the CMG numbers.

6. CASH

6.1. The Trust's held £2.9m of cash balance at the end of November 2013. The unmitigated year-end cash balance is forecast to be minus £6m as shown in the following graph:



- 6.2. We are taking action to ensure the year end cash balance is increased by at least £11m to £5m. These actions include:
 - managing the timing of expenditure within the capital programme; and
 - managing creditor payments.
- 6.3. To manage any in-month cash shortfalls local CCGs are continuing to pay us £21m of the monthly SLA payments to the start of each month instead of on the 15th of the month.

7. CAPITAL

7.1. The Trust has spent £16.1m of capital at the end of November 2013, which is approximately 75% of the YTD Plan. The year-end forecast, as shown with the appendices, is £35.5m, £4.3m below the planned level.

8. CONCLUSION

8.1. The Trust has reported to the NTDA that we are £23m adverse to our planned £2.7m surplus. The implications for the full year forecast are shown in a separate paper.

Andrew Seddon
Director of Finance and Business Services
20 December 2013

APPENDIX 1 - FINANCIAL APPENDICES

Income and Expenditure Account for the Period Ended 30 November 2013

		November 2013		April 20)13 - Novemb	er 2013
	Plan	Actual	Variance	Plan	Actual	Variance
	0.000	0.000	(Adv) / Fav	0.000	0.000	(Adv) / Fav
	£ 000	£ 000	£ 000	£ 000	£ 000	£ 000
Elective	5,826	6,325	499	,	•	378
Day Case	4,132		533	,	•	1,182
Emergency	14,545	•	(314)	115,507	114,661	(846)
Outpatient Contingency Release	6,933 0	7,481	548 0	55,901 5,000	58,608 5,000	2,707
Non NHS Patient Care	605	857	252	,	•	(1,009)
Winter funding	0	1,575	1,575	,	3,091	3,091
Other	21,783		1,475		•	3,327
Patient Care Income	53,824	58,391	4,567		439,394	8,830
Teaching, R&D income	5,718	5,628	(90)	51,151	50,549	(602)
Other operating Income	1,603	1,643	40	25,692	25,745	53
Total Income	61,145	65,662	4,517	507,407	515,688	8,281
Pay Expenditure	37,182	39,598	(2,416)	298,806	312,207	(13,401)
Non Pay Expenditure	23,890	25,365	(1,475)	184,115	194,848	(10,733)
Central Reserves	(4,112)	0	(4,112)	(7,604)	0	(7,604)
Total Operating Expenditure	56,960	64,963	(8,003)	475,317	507,055	(31,738)
EBITDA	4,185	699	(3,486)	32,090	8,633	(23,457)
Interest Receivable	7	4	(3)	55	128	73
Interest Payable	(5)	(4)	1	(40)	(137)	(97)
Depreciation & Amortisation	(2,707)	(2,733)	(26)	(21,654)	(21,501)	153
Surplus / (Deficit) Before						
Dividend and Disposal of Fixed						
Assets	1,480	(2,034)	(3,514)	10,451	(12,877)	(23,328)
Dividend Payable on PDC	(964)	(983)	(19)	(7,712)	(7,401)	311
Net Surplus / (Deficit)	516	(3,017)	(3,533)	2,739	(20,278)	(23,017)
EBITDA MARGIN		1.07%			1.67%	

Balance Sheet									
BALANCE SHEET	Mar-13 £000's Actual	Apr-13 £000's Actual	May-13 £000's Actual	Jun-13 £000's Actual	Jul-13 £000's Actual	Aug-13 £000's Actual	Sep-13 £000's Actual	Oct-13 £000's Actual	Nov-13 £000's Actual
Non Current Assets									
Intangible assets	5,318	5,160	5,012	4,940	4,795	4,650	4,627	4,419	4,273
Property, plant and equipment	354,680	353,855	353,723	352,327	352,803	353,255	352,521	352,993	353,114
Trade and other receivables	3,125	3,183	3,181	3,252	3,302	3,291	3,331	3,268	3,191
TOTAL NON CURRENT ASSETS	363,123	362,198	361,916	360,519	360,900	361,196	360,479	360,680	360,578
Current Assets									
Inventories	13,064	13,869	13,257	13,778	13,861	13,776	14,499	14,176	14,155
Trade and other receivables	44,616	42,408	42,628	35,756	40,713	44,182	46,674	42,210	49,634
Other Assets	40	40	40	40	40	40	40	40	40
Cash and cash equivalents	19,986	19,957	14,257	19,129	15,343	7,203	4,484	5,335	2,933
TOTAL CURRENT ASSETS	77,706	76,274	70,182	68,703	69,957	65,201	65,697	61,761	66,762
Current Liabilities	(75.550)	(70.050)	(07.074)	(00, 070)	(74,000)	(00.400)	(77,007)	(04.040)	(00.704)
Trade and other payables	(75,559)	(73,056)	(67,971)	(68,079)	(71,026)	(69,123)	(77,327) 0	(81,916)	(88,794)
Dividend payable Borrowings	(2,726)	(964) (2,800)	(1,928) (2,800)	(2,892) (2,800)	(3,856) (2,800)	(4,820) (2,800)	(2,800)	(964) (2,800)	(1,928) (2,800)
Provisions for liabilities and charges	(1,906)	(2,800)	(2,800)	(2,800) (1,906)	(2,800)	(2,800) (1,906)	(2,800)	(2,800)	(2,800)
TOTAL CURRENT LIABILITIES		` '	(74,605)	```	(79,588)	, , ,	, , ,		
TOTAL CORRENT LIABILITIES	(80,191)	(78,726)	(74,605)	(75,677)	(79,566)	(78,649)	(81,469)	(87,022)	(94,864)
NET CURRENT ASSETS (LIABILITIES)	(2,485)	(2,452)	(4,423)	(6,974)	(9,631)	(13,448)	(15,772)	(25,261)	(28,102)
TOTAL ASSETS LESS CURRENT LIABILITIES	360,638	359,746	357,493	353,545	351,269	347,748	344,707	335,419	332,476
Non Current Liabilities	000,000	000,140	001,400	000,040	001,200	047,740	011,707	000,410	002,410
Borrowings	(10,906)	(10,958)	(11,190)	(10,809)	(11,522)	(11,484)	(11,159)	(10,797)	(10,410)
Other Liabilities	, , ,	Ó	Ô	O	0	0	0	0	0
Provisions for liabilities and charges	(2,407)	(2,454)	(2,488)	(2,404)	(2,315)	(2,312)	(2,986)	(2,910)	(2,870)
TOTAL NON CURRENT LIABILITIES	(13,313)	(13,412)	(13,678)	(13,213)	(13,837)	(13,796)	(14,145)	(13,707)	(13,280)
TOTAL ASSETS EMPLOYED	347,325	346,334	343,815	340,332	337,432	333,952	330,562	321,712	319,196
Bullio dicidende escited	077 700	077 766	077 766	077 700	077 700	077 700	077 700	077 700	077 766
Public dividend capital	277,733	277,733	277,733	277,733	277,733	277,733	277,733	277,733	277,733
Revaluation reserve	64,628	64,626	64,628	64,632	64,632	64,628	64,628	64,628	64,628
Retained earnings	4,960	3,975	1,454	(2,033)	(4,933)	(8,409)	(11,799)	(20,649)	(23,165)
TOTAL TAXPAYERS EQUITY	347,325	346,334	343,815	340,332	337,432	333,952	330,562	321,712	319,196

Cash Flow Forecast

Cash Flow for the period ended 30th November 2013								
	2013/14 Apr - Nov Plan £ 000	2013/14 Apr - Nov Actual £ 000	2013/14 Apr - Nov Variance £ 000					
CASH FLOWS FROM OPERATING ACTIVITIES								
Operating surplus before Depreciation and Amortisation	32,378	8,633	(23,745)					
Donated assets received credited to revenue and non cash	(200)	(151)	49					
Interest paid	(563)	(565)	(2)					
Movements in Working Capital:								
- Inventories (Inc)/Dec	-	(1,091)	(1,091)					
- Trade and Other Receivables (Inc)/Dec	-	(5,084)	(5,084)					
- Trade and Other Payables Inc/(Dec)	-	8,997	8,997					
- Provisions Inc/(Dec)	(1,424)	(101)	1,323					
PDC Dividends paid	(5,500)	(5,454)	46					
Other non-cash movements	(273)	206	479					
Net Cash Inflow / (Outflow) from Operating Activities	24,418	5,390	(19,028)					
CASH FLOWS FROM INVESTING ACTIVITIES								
Interest Received	64	46	(18)					
Payments for Property, Plant and Equipment	(19,715)	(19,210)	505					
Capital element of finance leases	(3,080)	(3,279)	(199)					
Net Cash Inflow / (Outflow) from Investing Activities	(22,731)	(22,443)	288					
CASH FLOWS FROM FINANCING ACTIVITIES								
New PDC	_	_	_					
Other Capital Receipts	-		_					
Net Cash Inflow / (Outflow) from Financing	-	-	-					
Opening cash	19,986	19,986	-					
Increase / (Decrease) in Cash	1,687	(17,053)	(18,740)					
Closing cash	21,673	2,933	(18,740)					

Rolling 12 month cashflow forecast - December 2013 to November 2014											
2013/14 December Forecast £ 000	December January February Forecast Forecast Forecast		2013/14 March Forecast £ 000	2014-15 April Forecast £ 000	2014-15 May Forecast £ 000	2014-15 June Forecast £ 000	2014-15 July Forecast £ 000	2014/15 August Forecast £ 000	2014/15 September Forecast £ 000	2014/15 October Forecast £ 000	2014/15 November Forecast £ 001
3,658	5,321	1,279	3,366	2,098	5,468	2,098	5,468	5,468	2,971	6,341	4,719
(25)	(25)	(25)	(26)	(26)	(26)	(26)	(26)	(26)	(26)	(26)	4,719
(77)	(77)	(79)	(78)	(82)	(82)	(81)	(81)	(80)	(80)	(79)	(78)
(,,,	(**)	(10)	(10)	(02)	(02)	(01)	(01)	(00)	(00)	(10)	-
2,000	11,238	2,000	1,200	(2,869)	(10)	41	9	8	41	(11)	- 24
(2,500)	(2,500)	(2,500)	(4,000)	(83)	(83)	(83)	(83)	(83)	(83)	(83)	(83)
(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)
-	-	-	(5,454)	-	-	-	-	-	(5,615)	-	-
-	-	-	-	-	-	-	(21)	-	-	-	-
3,047	13,949	667	(5,000)	(970)	5,259	1,941	5,258	5,279	(2,800)	6,134	4,548
8	8	8	8	6	6	6	6	7	7	7	7
(2,251)	(2,252)	(2,251)	(4,409)	(2,294)	(2,295)	(2,294)	(2,295)	(2,294)	(2,295)	(2,294)	(2,295)
(400)	(400)	(400)	(400)	(391)	(391)	(391)	(391)	(391)	(391)	(391)	(391)
(2,644)	(2,644)	(2,643)	(4,801)	(2,679)	(2,680)	(2,679)	(2,680)	(2,678)	(2,679)	(2,678)	(2,679)
-	-	2,147	-	-	-	-	-	-	-	-	-
-	-	2,147	-	-	-	-	-	-	-		-
2,933	3,337	14,642	14,813	5,012	1,363	3,942	3,204	5,782	8,383	2,904	6,360
404	11,305	171	(9,801)	(3,649)	2,579	(738)	2,578	2,601	(5,479)	3,456	1,869
3,337	14,642	14,813	5,012	1,363	3,942	3,204	5,782	8,383	2,904	6,360	8,229

Capital Programme

	Capital	YTD	Expenditure Profile													
	Plan	Spend		Actual Forecast									Forecast			
	2013/14	13/14	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Out Turn	
	£000's	£000's	£000's	£000's	£000's	£000's	£000's	£000's	£000's	£000's	£000's	£000's	£000's	£000's	£000's	£'000's
Da assessat Davidsonta																
Recurrent Budgets	0.075	0.000	00	000	000	000	000	044	1 001	4.0	400	400	400	000	4 405	(4.050)
IM&T	3,375	2,829	69	226 7	290	203 119	688 386	311 347	1,031	12	400 72	400 0	400 518	396 930	, -	(1,050)
Medical Equipment	4,187	2,667	264		209			_	904	431		_			, -	0
Facilities Sub Group	6,000	1,888	286	204	193	388	261	143	78 50	334	500	750	1,250	1,612		0
Divisional Discretionary Capital	406	322	150	65	9	10	16	12	56	4	48	36	0	0		(750)
MES Installation Costs	1,750	1,582	38	178	343	455	40	403	32	92	200	200	250	268		(750)
Total Recurrent Budgets	15,718	9,287	807	680	1,045	1,174	1,392	1,215	2,102	872	1,220	1,386	2,418	3,206	17,518	(1,800)
Reconfiguration Schemes																
Emergency Floor	4,000	1,197	2	7	14	79	79	130	312	575	300	500	750	653	3,400	600
Theatres Assessment Area (TAA)	1,549	981	4	10	27	30	491	172	75	171	200	191	208	0	1,580	(31)
Advanced Recovery LRI & LGH	625	149	63	(7)	55	11	7	(6)	18	8		15	100	235		111
GGH Vascular Surgery	1,156	28	0	Ò	0	0	0	Ò	24	4	0	0	100	705		
Hybrid Theatre (Vascular)	500	0	0	0	0	0	0	0	0	0	0	0	0	0		500
Daycase / OPD Hub	350	0	0	0	0	0	0	0	0	0	0	0	0	0	0	350
GH Imaging	500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	500
Ward 4 LGH / H Block Isolation	283	1	0	0	0	0	0	0	1	0	32	50	100	100	283	0
GH Modular Wards * 2	4,050	0	0	0	0	0	0	0	0	0	43	0	0	0		4,007
Brandon Unit Refurb: OPD 1-4	2,000	106	0	0	0	0	5	4	1	95	0	0	0	16	122	1,878
ITU	140	0	0	0	0	0	0	0	0	0	0	0	0	0	0	140
Poppies Conversion	250	28	0	0	0	0	0	0	0	28	0	100	100	72	300	(50)
Feasibility Studies	100	33	0	0	0	0	0	0	35	(2)	5	5	5	12	60	40
Total Reconfiguration	15,503	2,523	70	10	96	121	582	300	465	880	595	861	1,363	1,793	7,135	8,368
Corporate / Other Schemes																
Osborne Ventilation	566	230	0	0	0	0	13	(1)	18	199	100	110	110	100	650	(84)
Endoscopy Redesign	250	152	0	80	(1)	24	5	28	16	1	14	0	0	0		84
Maternity Interim Development	2,800	1,547	3	18	9	273	388	332	190	334	330	362	354	407		
Aseptic Suite	650	17	7	0	1	0	0	2	5	1	150	150	150	183	,	(/
Diabetes BRU	600	719	Ó	62	125	128	141	37	105	121	1	0	0	0		(120)
Respiratory BRU	500	731	3	809	(245)	190	9	(46)	10	1	0	0	0	1	_	(232)
Stock Management System	3.000	187	0	0	0	0	0	0	3	185	_	800	1,000	993		
LIA Schemes	,,,,,,	0	0	0	0	0	0	0	0	0		100	150	150	-,	
CMG Contingency	194	0	0	0	0	0	0	0	0	0	44	50	50	50		(555)
Other Developments	0	742	163	123	91	36	69	(9)	104	163		100	100	178	-	(1,220)
care. 2 overepriorite	8,560	4,324	177	1,093	(20)	650	625	343	450	1,006	859	1,672	1,914	2,063		(2,272)
		,								·					Í	
Total Capital Programme	39,781	16,134	1,054	1,783	1,121	1,945	2,598	1,858	3,017	2,759	2,674	3,919	5,695	7,062	35,485	4,296

November - Actual Results against Forecast

	Variance compared to forecast - November							
		Non Pay	Income	Total				
	Pay £'000	£'000	£'000	£'000s				
C.H.U.G.S	7	(323)	392	76				
Clinical Support & Imaging	(64)	(188)	18	(234)				
Divisional Management Codes	(1)	(4)	0	(4)				
Emergency & Specialist Med	(46)	(227)	410	138				
I.T.A.P.S	(207)	(28)	(128)	(363)				
Musculo & Specialist Surgery	(153)	(110)	139	(124)				
Renal, Respiratory & Cardiac	11	(353)	321	(21)				
Womens & Childrens	(86)	(98)	660	476				
Total CMGs	(540)	(1,331)	1,813	(57)				
Communications & Ext Relations	(2)	(6)	(1)	(9)				
Corporate & Legal	7	19	0	26				
Corporate Medical	(2)	(54)	33	(24)				
Facilities	9	25	35	70				
Finance & Procurement	14	8	(O)	22				
Human Resources	9	(6)	19	22				
Im&T	(14)	(34)	1	(47)				
Nursing	48	(15)	(1)	33				
Operations	(32)	(32)	144	81				
Strategic Devt	(3)	(12)	(0)	(15)				
Total Corporate Directorates	35	(106)	230	159				
Total Central	(65)	(210)	(332)	(607)				
Research & Development	7	(38)	42	11				
Grand Total	(563)	(1,685)	1,753	(495)				